Can Buspirone Cause Recurrent Yawning or Problems Catching Your Breath?
Yes, buspirone can cause yawning, but it does not typically cause shortness of breath or respiratory problems—in fact, it may actually stimulate respiration rather than depress it.
Yawning as a Side Effect
Buspirone's effect on yawning is well-documented in the research literature. Yawning is a recognized adverse effect of buspirone, likely related to its serotonergic activity 1, 2. In animal studies, buspirone dose-dependently reduced apomorphine-induced yawning 2, but paradoxically, clinical observations in humans have noted yawning as an adverse effect during treatment 1.
The FDA drug label for buspirone does not specifically list yawning as a common adverse event in the formal clinical trials data 3, though this may reflect underreporting of what patients might consider a minor symptom. In primate studies, buspirone treatment was associated with decreased rates of yawning compared to fluoxetine-treated animals 1, suggesting the relationship between buspirone and yawning is complex and may be context-dependent.
Respiratory Effects: Stimulation, Not Depression
Regarding breathing difficulties, buspirone is actually unique among anxiolytics in that it stimulates rather than depresses respiration 4, 5. This is a critical distinction from benzodiazepines and other sedating anxiolytics:
- In controlled studies, buspirone had no effect on resting ventilation or CO2 response in normal subjects 4
- Unlike diazepam, buspirone did not depress respiratory center chemosensitivity 4
- Animal studies demonstrated that buspirone has a dose-dependent stimulatory effect on respiratory output, primarily through increased tidal activity 5
- In patients with chronic obstructive pulmonary disease (COPD), buspirone actually improved breathlessness and exercise tolerance without affecting respiratory drive, arterial blood gases, or respiratory mechanics 6
Clinical Implications for Respiratory Symptoms
If a patient reports "problems catching your breath" while on buspirone, this is unlikely to be a direct pharmacological effect of the medication. Instead, consider:
- Anxiety symptoms themselves: The sensation of dyspnea or air hunger is a common manifestation of anxiety disorders, which buspirone is meant to treat
- Serotonin syndrome: While rare, if respiratory symptoms are accompanied by agitation, confusion, tremor, diaphoresis, or hyperthermia, consider serotonin syndrome, particularly if buspirone is combined with other serotonergic agents 3
- Hyperventilation: Anxiety-related hyperventilation can create a subjective sensation of breathlessness despite adequate oxygenation
Common Side Effects to Anticipate
The most frequently reported adverse events with buspirone from controlled clinical trials include 3:
- Dizziness (12%) - most common
- Nausea (8%)
- Headache (6%)
- Nervousness (5%)
- Lightheadedness (3%)
- Drowsiness (10%)
A recent meta-analysis confirmed higher rates of dizziness, constipation, and gastric distress compared to placebo 7.
Important Safety Considerations
Contraindications and Warnings
- Do not combine with MAOIs - risk of elevated blood pressure and serotonin syndrome 3
- Monitor for serotonin syndrome when combined with other serotonergic drugs (SSRIs, SNRIs, triptans) 3
- Lower seizure threshold - noted as a limitation in cardiac arrest management guidelines 8
Advantages Over Benzodiazepines
Unlike benzodiazepines, buspirone:
- Does not cause respiratory depression 4, 5
- Has no sedative effects in most patients 3
- Does not exhibit cross-tolerance with sedative/hypnotic drugs 3
- May actually be safer in patients with lung disease 4
Clinical Recommendation
If your patient reports recurrent yawning on buspirone, this is a recognized but generally benign side effect that does not require discontinuation unless bothersome. However, if they report difficulty breathing or shortness of breath, investigate other causes rather than attributing it to buspirone, as this medication does not cause respiratory depression and may actually improve dyspnea in patients with underlying lung disease 6.
Consider evaluating for anxiety-related hyperventilation, serotonin syndrome (if on multiple serotonergic agents), or unrelated cardiopulmonary conditions. The respiratory stimulant properties of buspirone make it a particularly appropriate anxiolytic choice for patients with comorbid respiratory conditions 4, 5.